LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

LLY

758.12

+2.89%↑

JNJ

151.16

+1.45%↑

UNH

291.21

+7.79%↑

ABBV

182.59

+1.45%↑

NVO

64.13

-2.91%↓

Search

Cellectar Biosciences Inc

Aperta

0.25 4.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.22

Massimo

0.25

Metriche Chiave

By Trading Economics

Dipendenti

11

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-2.4M

11M

Apertura precedente

-3.92

Chiusura precedente

0.25

Cellectar Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 dic 2024, 18:44 UTC

I principali Market Mover

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Confronto tra pari

Modifica del prezzo

Cellectar Biosciences Inc Previsione

Consenso sulla valutazione

By TipRanks

Neutrale

2 ratings

0

Acquista

2

Mantieni

0

Vendi

Notizie finanziarie

$

Chi Siamo Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.